- Home
- MLTX vs DAWN Comparison
MLTX vs DAWN Comparison
Compare MLTX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- DAWN
- Stock Information
- Founded
- MLTX 2021
- DAWN 2018
- Country
- MLTX Switzerland
- DAWN United States
- Employees
- MLTX N/A
- DAWN N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- MLTX Health Care
- DAWN Health Care
- Exchange
- MLTX Nasdaq
- DAWN Nasdaq
- Market Cap
- MLTX 595.6M
- DAWN 624.8M
- IPO Year
- MLTX N/A
- DAWN 2021
- Fundamental
- Price
- MLTX $9.82
- DAWN $7.77
- Analyst Decision
- MLTX Buy
- DAWN Strong Buy
- Analyst Count
- MLTX 9
- DAWN 7
- Target Price
- MLTX $37.63
- DAWN $27.86
- AVG Volume (30 Days)
- MLTX 12.2M
- DAWN 1.4M
- Earning Date
- MLTX 11-07-2025
- DAWN 11-04-2025
- Dividend Yield
- MLTX N/A
- DAWN N/A
- EPS Growth
- MLTX N/A
- DAWN N/A
- EPS
- MLTX N/A
- DAWN N/A
- Revenue
- MLTX N/A
- DAWN $187,638,000.00
- Revenue This Year
- MLTX N/A
- DAWN $12.96
- Revenue Next Year
- MLTX N/A
- DAWN $48.40
- P/E Ratio
- MLTX N/A
- DAWN N/A
- Revenue Growth
- MLTX N/A
- DAWN 2190.50
- 52 Week Low
- MLTX $5.95
- DAWN $5.64
- 52 Week High
- MLTX $62.75
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- MLTX 27.40
- DAWN 57.91
- Support Level
- MLTX $8.92
- DAWN $7.15
- Resistance Level
- MLTX $9.47
- DAWN $7.77
- Average True Range (ATR)
- MLTX 0.62
- DAWN 0.35
- MACD
- MLTX 1.54
- DAWN 0.02
- Stochastic Oscillator
- MLTX 47.44
- DAWN 70.27
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.